Basilea Opens New Phase III Study In Special Patient Populations For Its Broad-spectrum Antifungal Isavuconazole

Basilea Pharmaceutica Ltd. (SWX: BSLN) announces that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole’s breadth of spectrum in vitro and its favorable pharmacokinetic profile formed the basis of this open label study.

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on April 17th, 2008